Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 17, Pages -Publisher
MDPI
DOI: 10.3390/ijms22179508
Keywords
DPP-IV inhibitors; PTP-1B inhibitors; alpha-glucosidase inhibitors; type 2 anti-diabetes; bioactive peptides; bioassay-guided methods
Funding
- Ministry of Science and Technology [MOST 110-2634-F-020-001]
- Animal Biologics Research of the Featured Area Research Center by Ministry of Education [MOST 110-2634-F-020-001]
- Animal Biologics Research of the Featured Area Research Center by Ministry of Science and Technology, Taiwan [MOST 110-2634-F-020-001]
Ask authors/readers for more resources
This review discusses the promising therapeutic strategies for managing type 2 diabetes, focusing on the inhibition of DPP-IV, PTP-1B, and alpha-glucosidase enzymes. Various food protein-derived antidiabetic bioactive peptides have been isolated and verified, showing potential for preventing and managing diabetes. Clinical studies are needed to validate the efficiency of these bioactive peptides before commercial applications.
Diabetes, a glucose metabolic disorder, is considered one of the biggest challenges associated with a complex complication of health crises in the modern lifestyle. Inhibition or reduction of the dipeptidyl peptidase IV (DPP-IV), alpha-glucosidase, and protein-tyrosine phosphatase 1B (PTP-1B) enzyme activities or expressions are notably considered as the promising therapeutic strategies for the management of type 2 diabetes (T2D). Various food protein-derived antidiabetic bioactive peptides have been isolated and verified. This review provides an overview of the DPP-IV, PTP-1B, and alpha-glucosidase inhibitors, and updates on the methods for the discovery of DPP-IV inhibitory peptides released from food-protein hydrolysate. The finding of novel bioactive peptides involves studies about the strategy of separation fractionation, the identification of peptide sequences, and the evaluation of peptide characteristics in vitro, in silico, in situ, and in vivo. The potential of bioactive peptides suggests useful applications in the prevention and management of diabetes. Furthermore, evidence of clinical studies is necessary for the validation of these peptides' efficiencies before commercial applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available